Dopamine transporter deficiency syndrome

Dopamine Transporter

Dopamine transporter deficiency syndrome (DTDS), also known as infantile parkinsonism-dystonia, is a rare genetic disorder that affects the dopamine transporter (DAT), a protein responsible for the reuptake of dopamine from the synapse back into the presynaptic neuron. This condition leads to a significant reduction in dopamine levels in the brain, resulting in severe motor and neurological symptoms.

Genetics

DTDS is caused by mutations in the SLC6A3 gene, which encodes the dopamine transporter protein. These mutations can lead to a loss of function of the transporter, impairing dopamine reuptake and causing an accumulation of dopamine in the synaptic cleft. The disorder is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Symptoms

The symptoms of DTDS typically appear in infancy or early childhood and may include:

• Severe parkinsonism, characterized by bradykinesia, rigidity, and tremors
• Dystonia, which involves involuntary muscle contractions and abnormal postures
• Hypotonia, or reduced muscle tone
• Developmental delay and intellectual disability
• Oculogyric crisis, a condition where the eyes move involuntarily upwards

Diagnosis

Diagnosis of DTDS is based on clinical evaluation, genetic testing, and the measurement of dopamine transporter function. Positron emission tomography (PET) scans can be used to assess the activity of the dopamine transporter in the brain. Genetic testing can confirm the presence of mutations in the SLC6A3 gene.

Treatment

There is currently no cure for DTDS, and treatment is primarily supportive and symptomatic. Management strategies may include:

• Levodopa therapy to increase dopamine levels in the brain
• Anticholinergic medications to reduce dystonia
• Physical therapy and occupational therapy to improve motor function and quality of life

Prognosis

The prognosis for individuals with DTDS varies depending on the severity of the symptoms and the effectiveness of the treatment. Early diagnosis and intervention can improve outcomes, but many individuals may experience significant motor and cognitive impairments throughout their lives.

See also

• Dopamine
• Parkinson's disease
• Dystonia
• Genetic disorders
• Neurotransmitter

External links

-

‎